Florida HIV Medication Cuts Threaten Public Health, Experts Warn
Recent changes to Florida’s AIDS Drug Assistance Program (ADAP) are raising serious concerns among healthcare professionals and HIV advocates. A novel emergency rule drastically reduces eligibility requirements and restricts access to essential medications, potentially leading to increased HIV infections and worsened health outcomes for vulnerable populations.
Eligibility Restrictions and Funding Cuts
Previously, Florida’s ADAP covered individuals earning up to 400% of the federal poverty level (FPL), which equates to under $64,000 annually for a single-person household in 2026 [1]. The new rule lowers the eligibility threshold to 130% of the FPL, or less than $21,000 per year for a single individual [7]. This change impacts an estimated 16,000 residents currently enrolled in the program [6].
The cuts are attributed to a reported $120 million budget deficit, rising insurance premiums, and declining federal assistance.
Impact on Medication Access
The revised ADAP formulary no longer includes Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), a widely prescribed once-daily HIV medication that accounts for 52% of new or changed prescriptions [8]. This restriction further limits treatment options for individuals relying on the program.
Expert Concerns and Projected Infections
Healthcare professionals are voicing strong concerns about the potential consequences of these changes. “This news is devastating,” says Aadia Rana, MD, an infectious diseases professor at the University of Alabama at Birmingham. “In a state that has the third highest rates of both new cases as well as those living with HIV in this country, any potential interruptions in HIV therapy… has the potential to increase the rate of uncontrolled virus and worsen outcomes for people living with HIV in Florida” [Source].
Preliminary analysis conducted by Melissa Schnure, PhD, a senior epidemiologist at the Johns Hopkins University School of Medicine, suggests that the cuts could lead to 4,312 additional HIV infections in Florida between 2026 and 2030 – a 28% increase compared to projections if ADAP remained unchanged [Source]. A similar simulation study indicated that eliminating the federal Ryan White HIV/AIDS Program, which funds state ADAPs, would result in a 73% surge in HIV infections nationwide.
National Trend of ADAP Cuts
Florida is not isolated in reducing HIV funding. Data from the National Association of State and Territorial AIDS Directors (NASTAD) indicates that 23 states and Washington, D.C., have implemented or are considering reductions to ADAP, although to a lesser extent than Florida [3].
Advocacy and Calls for Action
HIV advocates are urging Florida officials to reconsider the cuts and prioritize access to life-saving treatment. Anna K. Person, MD, chair of the HIV Medicine Association, stated that the disruptions “will result in a public health disaster” and called for a collaborative approach to address funding challenges [6].
The Florida Department of Health has not yet responded to requests for comment, but a statement on its website claims the changes are necessary to prevent a $120 million shortfall [Source].
Sources: